Ibrance trial failure dashes Pfizer’s growth hopes for the drug

Ibrance trial failure dashes Pfizer’s growth hopes for the drug

Source: 
Pharmaforum
snippet: 

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s rival drug Verzenio.